title: Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine.
abstract: Neisseria meningitidis serogroup C bactericidal titers and class-specific enzyme-linked immunosorbent assay (ELISA) antibody concentrations were measured in sera from 173 children (1 to 5 years old) before and 6 weeks and 7 months following vaccination with a quadrivalent (A/C/Y/W-135) polysaccharide vaccine. The immune responses of the children were compared with those of 40 adults 6 weeks postvaccination. Both bactericidal titers and ELISA antibody concentrations were significantly higher in the adults than in the children (P < 0.05). In addition, the ratio of immunoglobulin G (IgG) to IgM was higher in the children than in the adults. With an ELISA total antibody concentration of >/=2 microg/ml used as a measure of seroconversion, >/=84% of the individuals from each age group responded to the serogroup C polysaccharide. However, with a >/=4-fold-increase in bactericidal titer used, only 18% of 1-year-olds, 32% of 2-year-olds, and 50 to 60% of 3-, 4-, and 5-year-olds seroconverted. The ELISA results suggest that >50% of all children retained >/=2 microg of total antibody per ml at 7 months postimmunization. However, the bactericidal titers suggest that <10% of children <4 years old retained a >/=4-fold increase at 7 months following vaccination. Of particular note, 59 of 79 sera (75%) from the 1- and 2-year-olds had high ELISA antibody concentrations (2 to 20 microg/ml) with no associated bactericidal titer (<1:8). Discordant results between bactericidal titers and ELISA antibody concentrations were not explained by the presence of IgA blocking antibody or relative levels of IgG and IgM. The bactericidal results show age-dependent differences in the production and retention of antibody in young children immunized with serogroup C polysaccharide; these differences are not evident with the ELISA data.
authors.affiliation: Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. SHT5@CDC.GOV
authors.forename: S E
authors.initials: SE
authors.lastname: Maslanka
authors.forename: J W
authors.initials: JW
authors.lastname: Tappero
authors.forename: B D
authors.initials: BD
authors.lastname: Plikaytis
authors.forename: R S
authors.initials: RS
authors.lastname: Brumberg
authors.forename: J K
authors.initials: JK
authors.lastname: Dykes
authors.forename: L L
authors.initials: LL
authors.lastname: Gheesling
authors.forename: K B
authors.initials: KB
authors.lastname: Donaldson
authors.forename: A
authors.initials: A
authors.lastname: Schuchat
authors.forename: J
authors.initials: J
authors.lastname: Pullman
authors.forename: M
authors.initials: M
authors.lastname: Jones
authors.forename: J
authors.initials: J
authors.lastname: Bushmaker
authors.forename: G M
authors.initials: GM
authors.lastname: Carlone
mesh_terms: D000328:Adult; D000367:Age Factors; D000907:Antibodies, Bacterial / Q000097:blood*; D000918:Antibody Specificity; D001428:Bacterial Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007158:Immunologic Techniques; D007223:Infant; D008589:Meningococcal Infections / Q000145:classification / Q000276:immunology / Q000517:prevention & control*; D009009:Montana; D011135:Polysaccharides, Bacterial / Q000276:immunology / Q000627:therapeutic use*; D012703:Serotyping; D014611:Vaccination
chemical_list: D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D011135:Polysaccharides, Bacterial; C037676:meningococcal group C polysaccharide